{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T03:41:53Z","timestamp":1773373313839,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,1,8]],"date-time":"2022-01-08T00:00:00Z","timestamp":1641600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,8]],"date-time":"2022-01-08T00:00:00Z","timestamp":1641600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    <jats:italic>Objective<\/jats:italic>\n                    . To evaluate the efficacy and safety of apatinib combined with FOLFIRI in the first-line treatment of advanced metastatic colorectal cancer (mCRC) and explore potential factors of efficacy.\n                    <jats:italic>Methods<\/jats:italic>\n                    <jats:bold>\n                      <jats:italic>.<\/jats:italic>\n                    <\/jats:bold>\n                    Twenty mCRC patients treated at Affiliated Cancer Hospital of Shanxi Medical University from March 2017 to March 2019 were included according to the enrolment criteria. They provided informed consent and were treated with apatinib combined with FOLFIRI according to the scheduled regimen until disease progression or unacceptable toxicity occurred. The primary endpoint was OS. The secondary endpoints included PFS, ORR, DCRand safety. OS and PFS were calculated using Kaplan\u2013Meier curves. Univariate and multivariate Cox regression analyses were used to evaluate independent prognostic factors of OS and PFS. R was used to determine cut-off values for biochemical indicators. Forest maps were drawn for Cox univariate results and the relationships between NLR and ECOG, which were significant in univariate analysis, and OS were represented by Kaplan\u2013Meier curves.\n                    <jats:italic>Results<\/jats:italic>\n                    <jats:bold>\n                      <jats:italic>.<\/jats:italic>\n                    <\/jats:bold>\n                    The median OS and PFS were 16.135\u00a0months (95% CI: 9.211\u201322.929) and 6\u00a0months (95% CI: 5.425\u20136.525). Multivariate Cox analysis showed that NLR and CEA were independent prognostic factors. The most common grade 3\u20134 adverse events were hypertension, diarrhoea, increased alkaline phosphatase, decreased leukocytes and decreased neutrophils.\n                    <jats:italic>Conclusion<\/jats:italic>\n                    . Apatinib combined with FOLFIRI for the first-line treatment of advanced unresectable mCRC showed good efficacy and safety. The baseline NLR was predictive of efficacy, and a low baseline NLR (HR: 0.2895, P\u2009=\u20090.0084) was associated with improved OS.\n                  <\/jats:p>\n                  <jats:p>Clinical Research Registration Number: ChiCTR1800015308.<\/jats:p>","DOI":"10.1007\/s10637-021-01205-3","type":"journal-article","created":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T19:03:13Z","timestamp":1641582193000},"page":"340-348","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancer"],"prefix":"10.1007","volume":"40","author":[{"given":"Xuetong","family":"Rong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongmei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9681-2876","authenticated-orcid":false,"given":"Yusheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,8]]},"reference":[{"key":"1205_CR1","doi-asserted-by":"publisher","unstructured":"Erratum: Global cancer statistics (2018) GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries (2020). CA: a cancer j clinicians 70(4):313. https:\/\/doi.org\/10.3322\/caac.21609","DOI":"10.3322\/caac.21609"},{"issue":"1","key":"1205_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3760\/cma.j.issn.0253-3766.2018.01.002","volume":"40","author":"WQ Chen","year":"2018","unstructured":"Chen WQ, Li H, Sun KX, Zheng RS, Zhang SW, Zeng HM, Zou XN, Gu XY, He J (2018) Report of Cancer Incidence and Mortality in China, 2014. Zhonghua zhong liu za zhi [Chinese journal of oncology] 40(1):5\u201313. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-3766.2018.01.002","journal-title":"Zhonghua zhong liu za zhi [Chinese journal of oncology]"},{"key":"1205_CR3","doi-asserted-by":"publisher","unstructured":"Modest DP, Pant S, Sartore-Bianchi A (2019) Treatment sequencing in metastatic colorectal cancer. European j cancer (Oxford, England : 1990) 109:70\u201383.\u00a0https:\/\/doi.org\/10.1016\/j.ejca.2018.12.019","DOI":"10.1016\/j.ejca.2018.12.019"},{"issue":"2","key":"1205_CR4","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1200\/jco.2004.05.113","volume":"22","author":"C Tournigand","year":"2004","unstructured":"Tournigand C, Andr\u00e9 T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J clinical oncol\u202f: official j Am Soc Clinical Oncol 22(2):229\u2013237. https:\/\/doi.org\/10.1200\/jco.2004.05.113","journal-title":"J clinical oncol : official j Am Soc Clinical Oncol"},{"issue":"5","key":"1205_CR5","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40291-012-0007-2","volume":"16","author":"KA Lyseng-Williamson","year":"2012","unstructured":"Lyseng-Williamson KA (2012) Cetuximab: a guide to its use in combination with FOLFIRI in the first-line treatment of metastatic colorectal cancer in the USA. Mol Diagn Ther 16(5):317\u2013322. https:\/\/doi.org\/10.1007\/s40291-012-0007-2","journal-title":"Mol Diagn Ther"},{"issue":"23","key":"1205_CR6","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1001\/jama.2017.7105","volume":"317","author":"AP Venook","year":"2017","unstructured":"Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, Schrag D, Greene C, O\u2019Neil BH, Atkins JN, Berry S, Polite BN, O\u2019Reilly EM, Goldberg RM, Hochster HS, Schilsky RL, Bertagnolli MM, El-Khoueiry AB, Watson P, Benson AB 3rd, Mulkerin DL, Mayer RJ, Blanke C (2017) Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA 317(23):2392\u20132401. https:\/\/doi.org\/10.1001\/jama.2017.7105","journal-title":"JAMA"},{"issue":"2","key":"1205_CR7","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s10555-017-9668-y","volume":"36","author":"EJ van Helden","year":"2017","unstructured":"van Helden EJ, der Houven M-V, van Oordt CW, Heymans MW, Ket JCF, van den Oord R, Verheul HMW (2017) Optimal use of anti-EGFR monoclonal antibodies for patients with advanced colorectal cancer: a meta-analysis. Cancer Metastasis Rev 36(2):395\u2013406. https:\/\/doi.org\/10.1007\/s10555-017-9668-y","journal-title":"Cancer Metastasis Rev"},{"issue":"7","key":"1205_CR8","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1634\/theoncologist.2019-0164","volume":"24","author":"X Chen","year":"2019","unstructured":"Chen X, Qiu T, Zhu Y, Sun J, Li P, Wang B, Lin P, Cai X, Han X, Zhao F, Shu Y, Chang L, Jiang H, Gu Y (2019) A Single-Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer. Oncologist 24(7):883-e407. https:\/\/doi.org\/10.1634\/theoncologist.2019-0164","journal-title":"Oncologist"},{"issue":"9454","key":"1205_CR9","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/s0140-6736(05)17706-x","volume":"365","author":"J Weitz","year":"2005","unstructured":"Weitz J, Koch M, Debus J, H\u00f6hler T, Galle PR, B\u00fcchler MW (2005) Colorectal cancer. Lancet (London, England) 365(9454):153\u2013165. https:\/\/doi.org\/10.1016\/s0140-6736(05)17706-x","journal-title":"Lancet (London, England)"},{"issue":"8","key":"1205_CR10","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s11894-019-0703-8","volume":"21","author":"EF Onyoh","year":"2019","unstructured":"Onyoh EF, Hsu WF, Chang LC, Lee YC, Wu MS, Chiu HM (2019) The Rise of Colorectal Cancer in Asia: Epidemiology, Screening, and Management. Curr Gastroenterol Rep 21(8):36. https:\/\/doi.org\/10.1007\/s11894-019-0703-8","journal-title":"Curr Gastroenterol Rep"},{"issue":"40","key":"1205_CR11","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000008242","volume":"96","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Chen Z, Li J (2017) The current status of treatment for colorectal cancer in China: A systematic review. Medicine 96(40):e8242. https:\/\/doi.org\/10.1097\/md.0000000000008242","journal-title":"Medicine"},{"key":"1205_CR12","doi-asserted-by":"publisher","first-page":"24460","DOI":"10.1038\/srep24460","volume":"6","author":"MA Aziz","year":"2016","unstructured":"Aziz MA, Serya RA, Lasheen DS, Abdel-Aziz AK, Esmat A, Mansour AM, Singab AN, Abouzid KA (2016) Discovery of Potent VEGFR-2 Inhibitors based on Furopyrimidine and Thienopyrimidne Scaffolds as Cancer Targeting Agents. Sci Rep 6:24460. https:\/\/doi.org\/10.1038\/srep24460","journal-title":"Sci Rep"},{"key":"1205_CR13","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1186\/1471-2407-10-529","volume":"10","author":"J Li","year":"2010","unstructured":"Li J, Zhao X, Chen L, Guo H, Lv F, Jia K, Yv K, Wang F, Li C, Qian J, Zheng C, Zuo Y (2010) Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies. BMC Cancer 10:529. https:\/\/doi.org\/10.1186\/1471-2407-10-529","journal-title":"BMC Cancer"},{"key":"1205_CR14","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.canlet.2018.05.046","volume":"431","author":"X Cheng","year":"2018","unstructured":"Cheng X, Feng H, Wu H, Jin Z, Shen X, Kuang J, Huo Z, Chen X, Gao H, Ye F, Ji X, Jing X, Zhang Y, Zhang T, Qiu W, Zhao R (2018) Targeting autophagy enhances apatinib-induced apoptosis via endoplasmic reticulum stress for human colorectal cancer. Cancer Lett 431:105\u2013114. https:\/\/doi.org\/10.1016\/j.canlet.2018.05.046","journal-title":"Cancer Lett"},{"issue":"9","key":"1205_CR15","doi-asserted-by":"publisher","first-page":"990","DOI":"10.22038\/ijbms.2017.9263","volume":"20","author":"W Lu","year":"2017","unstructured":"Lu W, Ke H, Qianshan D, Zhen W, Guoan X, Honggang Y (2017) Apatinib has anti-tumor effects and induces autophagy in colon cancer cells. Iran J Basic Med Sci 20(9):990\u2013995. https:\/\/doi.org\/10.22038\/ijbms.2017.9263","journal-title":"Iran J Basic Med Sci"},{"key":"1205_CR16","doi-asserted-by":"publisher","first-page":"11031","DOI":"10.2147\/ott.S266549","volume":"13","author":"X Cai","year":"2020","unstructured":"Cai X, Wei B, Li L, Chen X, Yang J, Li X, Jiang X, Lv M, Li M, Lin Y, Xu Q, Guo W, Gu Y (2020) Therapeutic Potential of Apatinib Against Colorectal Cancer by Inhibiting VEGFR2-Mediated Angiogenesis and \u03b2-Catenin Signaling. Onco Targets Ther 13:11031\u201311044. https:\/\/doi.org\/10.2147\/ott.S266549","journal-title":"Onco Targets Ther"},{"issue":"50","key":"1205_CR17","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000013635","volume":"97","author":"X Liao","year":"2018","unstructured":"Liao X, Li H, Liu Z, Liao S, Li Q, Liang C, Huang Y, Xie M, Wei J, Li Y (2018) Clinical efficacy and safety of apatinib in patients with advanced colorectal cancer as the late-line treatment. Medicine 97(50):e13635. https:\/\/doi.org\/10.1097\/md.0000000000013635","journal-title":"Medicine"},{"issue":"2","key":"1205_CR18","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3892\/mco.2017.1307","volume":"7","author":"N Takeuchi","year":"2017","unstructured":"Takeuchi N, Koike K, Yoshida S, Kudo A, Sekiguchi N, Nakayama A, Kubota K, Rokuhara T, Kitahara M (2017) Treatment of metastatic refractory colorectal cancer following regorafenib failure. Molecular and clinical oncol 7(2):308\u2013312. https:\/\/doi.org\/10.3892\/mco.2017.1307","journal-title":"Molecular and clinical oncol"},{"issue":"6","key":"1205_CR19","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/s1470-2045(15)70156-7","volume":"16","author":"J Li","year":"2015","unstructured":"Li J, Qin S, Xu R, Yau TC, Ma B, Pan H, Xu J, Bai Y, Chi Y, Wang L, Yeh KH, Bi F, Cheng Y, Le AT, Lin JK, Liu T, Ma D, Kappeler C, Kalmus J, Kim TW (2015) Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 16(6):619\u2013629. https:\/\/doi.org\/10.1016\/s1470-2045(15)70156-7","journal-title":"Lancet Oncol"},{"issue":"1","key":"1205_CR20","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1186\/s12885-019-5753-7","volume":"19","author":"A Carrato","year":"2019","unstructured":"Carrato A, Benavides M, Massut\u00ed B, Ferreiro-Monteagudo R, Garc\u00eda Alfonso P, Falc\u00f3 E, Reboredo M, Cano T, Gallego J, Vi\u00e9itez JM, Layos L, Salud A, Polo E, Dotor E, Dur\u00e1n-Ogalla G, Rodriguez-Garrote M, Calvo A, Grande E, Aranda E (2019) First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). BMC Cancer 19(1):533. https:\/\/doi.org\/10.1186\/s12885-019-5753-7","journal-title":"BMC Cancer"},{"issue":"2","key":"1205_CR21","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jcmgh.2017.01.006","volume":"3","author":"LR Zarour","year":"2017","unstructured":"Zarour LR, Anand S, Billingsley KG, Bisson WH, Cercek A, Clarke MF, Coussens LM, Gast CE, Geltzeiler CB, Hansen L, Kelley KA, Lopez CD, Rana SR, Ruhl R, Tsikitis VL, Vaccaro GM, Wong MH, Mayo SC (2017) Colorectal Cancer Liver Metastasis: Evolving Paradigms and Future Directions. Cell Mol Gastroenterol Hepatol 3(2):163\u2013173. https:\/\/doi.org\/10.1016\/j.jcmgh.2017.01.006","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"1205_CR22","doi-asserted-by":"publisher","first-page":"11645","DOI":"10.2147\/ott.S271955","volume":"13","author":"X Yu","year":"2020","unstructured":"Yu X, Zhu L, Liu J, Xie M, Chen J, Li J (2020) Emerging Role of Immunotherapy for Colorectal Cancer with Liver Metastasis. Onco Targets Ther 13:11645\u201311658. https:\/\/doi.org\/10.2147\/ott.S271955","journal-title":"Onco Targets Ther"},{"key":"1205_CR23","doi-asserted-by":"publisher","unstructured":"Li J, Yuan Y, Yang F, Wang Y, Zhu X, Wang Z, Zheng S, Wan D, He J, Wang J, Ba Y, Bai C, Bai L, Bai W, Bi F, Cai K, Cai M, Cai S, Chen G, Chen K, Chen L, Chen P, Chi P, Dai G, Deng Y, Ding K, Fan Q, Fang W, Fang X, Feng F, Fu C, Fu Q, Gu Y, He Y, Jia B, Jiang K, Lai M, Lan P, Li E, Li D, Li J, Li L, Li M, Li S, Li Y, Li Y, Li Z, Liang X, Liang Z, Lin F, Lin G, Liu H, Liu J, Liu T, Liu Y, Pan H, Pan Z, Pei H, Qiu M, Qu X, Ren L, Shen Z, Sheng W, Song C, Song L, Sun J, Sun L, Sun Y, Tang Y, Tao M, Wang C, Wang H, Wang J, Wang S, Wang X, Wang X, Wang Z, Wu A, Wu N, Xia L, Xiao Y, Xing B, Xiong B, Xu J, Xu J, Xu N, Xu R, Xu Z, Yang Y, Yao H, Ye Y, Yu Y, Yu Y, Yue J, Zhang J, Zhang J, Zhang S, Zhang W, Zhang Y, Zhang Z, Zhang Z, Zhao L, Zhao R, Zhou F, Zhou J, Jin J, Gu J, Shen L (2019) Expert consensus on multidisciplinary therapy of colorectal cancer with lung metastases (2019 edition). J hematol oncol 12(1):16. https:\/\/doi.org\/10.1186\/s13045-019-0702-0","DOI":"10.1186\/s13045-019-0702-0"},{"issue":"1","key":"1205_CR24","doi-asserted-by":"publisher","first-page":"6058","DOI":"10.1038\/s41598-020-62961-5","volume":"10","author":"F Wang","year":"2020","unstructured":"Wang F, Yuan X, Jia J, Bi X, Zhou Z, Zhou Q, Li X, Luo C, Deng M, Yi L, Li Y, Lu J, Su W, Chen H, Zhu Y, Wang S (2020) Apatinib Monotherapy for Chemotherapy-Refractory Metastatic Colorectal Cancer: A Multi-centre, Single-Arm. Prospective Study Scientific reps 10(1):6058. https:\/\/doi.org\/10.1038\/s41598-020-62961-5","journal-title":"Prospective Study Scientific reps"},{"issue":"4","key":"1205_CR25","doi-asserted-by":"publisher","first-page":"e741","DOI":"10.1016\/j.clcc.2018.08.002","volume":"17","author":"Y Sunakawa","year":"2018","unstructured":"Sunakawa Y, Yang D, Cao S, Zhang W, Moran M, Astrow SH, Hsiang J, Stephens C, Tsuji A, Takahashi T, Tanioka H, Negoro Y, Takagane A, Tani S, Yamaguchi T, Eto T, Fujii M, Ichikawa W, Lenz HJ (2018) Immune-related Genes to Dominate Neutrophil-lymphocyte Ratio (NLR) Associated With Survival of Cetuximab Treatment in Metastatic Colorectal Cancer. Clin Colorectal Cancer 17(4):e741\u2013e749. https:\/\/doi.org\/10.1016\/j.clcc.2018.08.002","journal-title":"Clin Colorectal Cancer"},{"issue":"9","key":"1205_CR26","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1158\/1078-0432.Ccr-18-3684","volume":"25","author":"R Ogawa","year":"2019","unstructured":"Ogawa R, Yamamoto T, Hirai H, Hanada K, Kiyasu Y, Nishikawa G, Mizuno R, Inamoto S, Itatani Y, Sakai Y, Kawada K (2019) Loss of SMAD4 Promotes Colorectal Cancer Progression by Recruiting Tumor-Associated Neutrophils via the CXCL1\/8-CXCR2 Axis. Clinical cancer res\u202f: an official j Am Association for Cancer Res 25(9):2887\u20132899. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-3684","journal-title":"Clinical cancer res : an official j Am Association for Cancer Res"},{"key":"1205_CR27","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ijsu.2018.05.030","volume":"55","author":"D Tan","year":"2018","unstructured":"Tan D, Fu Y, Tong W, Li F (2018) Prognostic significance of lymphocyte to monocyte ratio in colorectal cancer: A meta-analysis. Int j surg (London, England) 55:128\u2013138. https:\/\/doi.org\/10.1016\/j.ijsu.2018.05.030","journal-title":"Int j surg (London, England)"},{"issue":"10","key":"1205_CR28","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1002\/ijc.28536","volume":"134","author":"MX Li","year":"2014","unstructured":"Li MX, Liu XM, Zhang XF, Zhang JF, Wang WL, Zhu Y, Dong J, Cheng JW, Liu ZW, Ma L, Lv Y (2014) Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis. Int J Cancer 134(10):2403\u20132413. https:\/\/doi.org\/10.1002\/ijc.28536","journal-title":"Int J Cancer"},{"issue":"3","key":"1205_CR29","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/sj.bjc.6600466","volume":"87","author":"HR Scott","year":"2002","unstructured":"Scott HR, McMillan DC, Forrest LM, Brown DJ, McArdle CS, Milroy R (2002) The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br J Cancer 87(3):264\u2013267. https:\/\/doi.org\/10.1038\/sj.bjc.6600466","journal-title":"Br J Cancer"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-021-01205-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-021-01205-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-021-01205-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T23:42:10Z","timestamp":1678491730000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-021-01205-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,8]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1205"],"URL":"https:\/\/doi.org\/10.1007\/s10637-021-01205-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-833709\/v1","asserted-by":"object"}]},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,8]]},"assertion":[{"value":"24 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is registered with ClinicalTrials.gov, number: ChiCTR1800015308. This study was performed in line with the princi-ples of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Shanxi Cancer Hospital, and a signed informed consent was obtained from all the participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"The authors declare that there is no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}